Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine
Portfolio Pulse from Vandana Singh
Tonix Pharmaceuticals (NASDAQ:TNXP) has partnered with Bilthoven Biologicals, part of the Cyrus Poonawalla Group, to advance its mpox vaccine candidate, TNX-801. The vaccine has shown promising preclinical results in providing immune protection against mpox and smallpox. This collaboration could enhance Tonix's position in the vaccine market.
August 26, 2024 | 2:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals has partnered with Bilthoven Biologicals to advance its mpox vaccine candidate, TNX-801. The vaccine has shown promising preclinical results, and the partnership could enhance Tonix's market position.
The partnership with a major vaccine manufacturer and the promising preclinical results of TNX-801 are likely to boost investor confidence in Tonix Pharmaceuticals. The stock price increase of 9.76% reflects positive market sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100